Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Centralizes Internal Procedure For SEC Communications

This article was originally published in The Gray Sheet

Executive Summary

FDA's new process for referring information to the Securities & Exchange Commission could result in heightened CDRH attention to potentially false or misleading statements by device firms

You may also be interested in...



SEC Suspends BioCurex Trading, Questions Firm’s Regulatory Claims

Press releases claiming "FDA-approved" status for BioCurex' Class I Histo-RECAF alpha-fetoprotein (AFP) tissue staining test played a role in SEC's decision to halt trading of the company's stock April 8

FDA/SEC Communication Enhancement Effort Gauged At FDLI

Device manufacturers should take extra care to present a uniform message to FDA and CMS concerning new devices to avoid running afoul of the Securities & Exchange Commission, Latham & Watkins Partner John Manthei advised April 15

SEC Suspends BioCurex Trading, Questions Firm’s Regulatory Claims

Press releases claiming "FDA-approved" status for BioCurex' Class I Histo-RECAF alpha-fetoprotein (AFP) tissue staining test played a role in SEC's decision to halt trading of the company's stock April 8

Related Content

UsernamePublicRestriction

Register

LL1134885

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel